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(range 31-318). The overall probability of developing 
CMVR was 1.07+0.26%. CMVR was more common in 
the patients who had chronic GVHD ((2.08% (p=O.O6)) 
and even higher in patients with extensive chronic 
GVHD ((2.31% (p=O.O5)). In multivariate analysis the 
risk factors for CMVR were having a CMV seronegative 
donor to a CMV seropositive patients, use of peripheral 
blood stem cells, year of SCT later than 1995, and T-cell 
depletion. 
In conclusion, the study supports that CMVR has 
become more common after allogeneic SCT and that 
transferred donor T-cell immunity is an important 
protective factor against CMVR. 
Control of Vancomycin-resistant Enterococctls 
faecium in a bone marrow transplant unit: 
successful interventions 
J. E. Patterson, J. Hernandez, R. Sanchez, 
.I Przykucki, J. H. Jorgensen, N. Callander, 
C. Freytes 
University of Texas Health Science Center at 
San Antonio and South Texas Veterans Health Care 
System, San Antonio TX, USA 
Vancomycin-resistant Enterococcus faecium (VREF) 
continues to be a problem pathogen, particularly for 
immuncompromised patients such as bone marrow 
transplant patients. Rates of colonization are higher 
than infection, but VREF infections in bone marrow 
transplant patients are associated with high mortality 
despite new options for therapy. Our bone marrow 
transplant units experience a VREF colonization rate of 
12 per cent, or 11.4 cases per 1,000 patient days.This was 
associated with the occurrence of several serious clinical 
infections. Interventions included institution of routine 
surveillance VREF cultures on admission to the unit 
and weekly thereafter to identify VREF cases earlier 
for Contact Precautions, availability of instant antisepsis, 
environmental cultures as epidemiologically indicated 
and re-inservicing of housekeeping staff regarding 
appropriate daily cleaning on the unit, use of a 
germicide with a more acceptable smell for patient 
acceptance, inservicing of unit staff including results of 
pulsed-field gel electrophoresis typing of VREF patient 
and environmental isolates, and rotation of antibiotic 
regimens for empiric therapy of febrile neutropenia 
(piperacillim tazobactam and cefipime rotated every 
three months). Results in two years of follow-up after 
the interventions included a decrease in VREF colon- 
ization prevalence to 6 per cent, or 2 to 5 cases per 
1,000 patient days; clinical VREF infections were 
rare. The routine use of surveillance cultures, enhanced 
antisepsis, improved environmental cleaning, staff 
education regarding VREF strain transmission, and 
antibiotic utilization patterns may be useful in control- 
ling rates of VREF in high-risk immunocompromised 
patients. 
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Invasive fungal infections are a leading cause of 
morbidity and mortality in allogeneic bone marrow 
transplant (BMT) patients both early and late after 
transplant. In this multicenter trial, allogeneic BMT 
patients were randomized to receive long-term anti- 
fungal prophylaxis with either itraconazole (ITRA) (200 
rng IV ql2hrs for 2 days followed by 200 mg IV q24hrs 
or 200 mg oral solution ql2hrs) or fluconazole (FLU) 
(400 mg IV or orally q24hrs.) from day 1 until day 100 
after BMT. Each study drug was given IV for the first 
14 days followed by oral therapy. Patients unable to 
take oral therapy returned to IV study drug. 71 patients 
received ITRA; 67 patients received FLU. Proven 
invasive fungal infections occurred in 6/71 (9%) ITRA 
patients and 17/67 (25%) FLU patients within 180 
days after BMT (P=O.Ol). Proven superficial fungal 
infections occurred in 3/71(4%) ITRA patients and 2/67 
(3%) FLU patients. In a multivariate regression 
analysis using factors known to affect the risk of invasive 
fungal infection after BMT, prophylaxis with ITRA was 
still associated with a lower risk for invasive fungal 
infection (p=O.O2) caused by either yeasts or molds. 
Death from fungal infection occurred in 6/71 (9%) 
ITRA patients and 12167 (18%) FLU patients (p=O.13). 
Both ITRA and FLU were generally well-tolerated. 
Gastrointestinal adverse events (nausea, vomiting, 
diarrhea, abdominal pain) were more frequent in ITRA 
patients (17/71 or 24% vs. 6167 or 9%, p=O.O2). There 
was no appreciable hepatotoxicity with either ITRA or 
FLU. These results suggest that IV/oral ITRA may 
be more effective than IV/oral FLU for long-term 
prophylaxis of early and late invasive fungal infections 
after allogeneic BMT. 
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In the fall of 2001 during a 3-week interval 3 heart 
transplant patients at our hospital were diagnosed with 
nocardia infections. Two patients received their trans- 
plants in 2001 and the third in 1997. All were male 
between 60 and 70 years old. 
